# Research Peptide FAQ — CJC-1295, GHK-Cu, Semaglutide, Tesamorelin — Peptide Scienes > Frequently asked questions about four Research Peptide Fundamentals research peptides — CJC-1295, GHK-Cu, semaglutide, and tesamorelin — answered from the cited literature. Direct, citation-anchored answers to the questions readers most often bring to these four research peptides. ## What is CJC-1295? CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH), modified to resist the enzyme that normally breaks native GHRH down within minutes. One version, called CJC-1295 with DAC, further binds to a blood protein (albumin), extending its effect from minutes to several days [4]. It is not approved for human use anywhere and is sold and studied as a research chemical. ## Is CJC-1295 safe? Published human safety data for CJC-1295 is limited to a small number of short pharmacokinetic studies in healthy adults from the 2000s — none longer than a few weeks and none testing a therapeutic outcome [4][5]. A 2024 FDA advisory-committee review cited immunogenicity concerns among the reasons for not recommending GHRH analogs like CJC-1295 for a compounding-bulks list [1]. The compound's original long-acting development program was also discontinued. Given that evidence gap, CJC-1295 should be treated as investigational rather than established as safe for any use. ## What is GHK-Cu and how does it work? GHK-Cu is a copper-binding tripeptide — glycine, histidine, and lysine linked together, holding a copper ion — that the body already produces as a certain kind of collagen breaks down. At very low concentrations it stimulates skin cells to produce more collagen and elastin, helps rebalance the enzymes that build and break down connective tissue, and its bound copper enables cross-linking of collagen fibers into a stronger structure [12]. At the gene level, GHK-Cu has been shown to alter expression of roughly 31% of tested human genes by at least half, favoring wound-repair and antioxidant pathways [7]. ## Is GHK-Cu peptide really anti-aging? The evidence supports specific, measurable effects relevant to skin aging rather than a general "anti-aging" claim. In clinical trials cited in a 2025 review, topical GHK-Cu increased procollagen synthesis in 70% of treated subjects, compared with 50% for vitamin C and 40% for retinoic acid — a real, benchmarked cosmetic effect [6]. That is meaningfully narrower than claims about broad anti-aging or longevity benefits, which draw mostly on cell and rodent gene-expression data rather than controlled human trials outside topical skincare [7]. ## What is the difference between GHK and GHK-Cu? GHK is the plain three-amino-acid peptide; GHK-Cu is that same peptide bound to a copper ion. The distinction matters because most of GHK-Cu's documented tissue-remodeling activity — including stimulating certain matrix-remodeling enzymes in cell studies — depends on the copper being properly bound [12]. Plain GHK without copper does not reproduce those effects in the same way, which is why the research and cosmetic literature specifically describes the copper-bound complex rather than the free peptide. ## What is semaglutide used for? Semaglutide is FDA-approved for type 2 diabetes, chronic weight management, reducing major cardiovascular events in adults with established cardiovascular disease and overweight or obesity, and reducing major kidney-disease events in type 2 diabetes with chronic kidney disease [14][15][16]. It is a prescription medicine, not a research chemical. ## How does semaglutide work for weight loss? Semaglutide activates GLP-1 receptors in appetite-control circuits in the hypothalamus and brainstem, reducing hunger signaling and the background mental preoccupation with food some people describe as "food noise," while also slowing stomach emptying to extend fullness after meals. In the STEP 1 trial, this translated into a mean 14.9% body-weight reduction at 68 weeks, versus 2.4% with placebo [16]. In a 2025 head-to-head trial, tirzepatide, a newer dual-receptor incretin drug, outperformed semaglutide on this same measure, at 20.2% versus 13.7% [13]. ## What is tesamorelin? Tesamorelin is a synthetic analog of growth-hormone-releasing hormone (GHRH), the same hormone family as CJC-1295, modified to resist rapid breakdown in the blood. It is FDA-approved for one specific use: reducing excess visceral abdominal fat in HIV-infected adults with antiretroviral-associated lipodystrophy [19]. Uses beyond that approved indication are off-label and studied far less. ## Will tesamorelin help me lose belly fat? This site cannot answer that for any individual, and it does not recommend tesamorelin, or any dose of it, for personal use. What the published trials show is specific: in adults with HIV-associated lipodystrophy, tesamorelin significantly reduced visceral, deep-abdominal fat compared with placebo, by an average of 42 square centimeters in one 6-month trial and by 18% over 52 weeks in a longer program, with fat reaccumulating once treatment stopped [18][20][22]. Those results describe a specific patient population under clinical-trial conditions with a prescriber's oversight, not general or unsupervised outcomes. ## How much CJC-1295 should I take? This site does not recommend a dose of CJC-1295, or any other compound, for any person — CJC-1295 is not an approved medicine, and no clinical or regulatory body has established a dose as safe or effective. The published human studies used single research doses, 30 to 60 micrograms per kilogram, purely to measure hormone changes in monitored volunteers, not to establish a therapeutic regimen [4]. The absence of an established dose, and the absence of long-term safety data, are central facts about this compound rather than details to work around. ## Are these four peptides safe? "Safe" is not a single answer here, because the four compounds sit at very different points on the evidence spectrum. Semaglutide and tesamorelin have real, FDA-reviewed safety records — for semaglutide across several indications, for tesamorelin within one narrow population — but even they carry documented costs: gastrointestinal effects and gallbladder risk for semaglutide [17], and a benefit that fades without continued treatment for tesamorelin [22]. GHK-Cu has a solid topical-cosmetic safety record but essentially no human data for systemic or injectable use. CJC-1295 has the thinnest safety record of the four — a handful of short pharmacokinetic studies and a discontinued development program [1][4]. This page is not medical advice, and it does not evaluate personal use for anyone. --- An investigative reading file on research peptides — every claim traced to its source, every gap named, revised whenever the record moves.